Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.

2.50
Hdl Handle:
http://hdl.handle.net/2436/620470
Title:
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
Authors:
Sherer, Christopher; Tolaymat, Ibrahim; Rowther, Farzana; Warr, Tracy; Snape, Timothy J
Abstract:
The prognosis for glioblastoma patients is, at best, poor, with the median time of survival after diagnosis measured in months. As such, there is much need for the rapid development of potent and novel treatments. Herein, we report our preliminary findings on the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with low micromolar activity against a particularly resistant glioblastoma cell culture, providing a new platform for future development of a new therapy in this area.
Citation:
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells. 2017, 27 (7):1561-1565 Bioorg. Med. Chem. Lett.
Publisher:
Elsevier
Journal:
Bioorganic & medicinal chemistry letters
Issue Date:
1-Apr-2017
URI:
http://hdl.handle.net/2436/620470
DOI:
10.1016/j.bmcl.2017.02.033
PubMed ID:
28256372
Type:
Article
Language:
en
ISSN:
0960-894X
Appears in Collections:
FSE

Full metadata record

DC FieldValue Language
dc.contributor.authorSherer, Christopheren
dc.contributor.authorTolaymat, Ibrahimen
dc.contributor.authorRowther, Farzanaen
dc.contributor.authorWarr, Tracyen
dc.contributor.authorSnape, Timothy Jen
dc.date.accessioned2017-05-10T14:21:57Z-
dc.date.available2017-05-10T14:21:57Z-
dc.date.issued2017-04-01-
dc.identifier.citationPreliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells. 2017, 27 (7):1561-1565 Bioorg. Med. Chem. Lett.en
dc.identifier.issn0960-894Xen
dc.identifier.pmid28256372-
dc.identifier.doi10.1016/j.bmcl.2017.02.033-
dc.identifier.urihttp://hdl.handle.net/2436/620470-
dc.description.abstractThe prognosis for glioblastoma patients is, at best, poor, with the median time of survival after diagnosis measured in months. As such, there is much need for the rapid development of potent and novel treatments. Herein, we report our preliminary findings on the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with low micromolar activity against a particularly resistant glioblastoma cell culture, providing a new platform for future development of a new therapy in this area.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Bioorganic & medicinal chemistry lettersen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectindole-3-carbinolen
dc.subject3,3’-diindoloylmethaneen
dc.subjectglioblastomaen
dc.subjectCanceren
dc.subjectSARen
dc.titlePreliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.en
dc.typeArticleen
dc.identifier.journalBioorganic & medicinal chemistry lettersen
dc.date.accepted2017-02-15-
rioxxterms.funderSydney Driscoll Neuroscience Foundation; Brain Tumour North Westen
rioxxterms.identifier.projectUOW100570TWen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2018-02-17en

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.